Acute renal failure after treatment with sunitinib in a patient with multiple myeloma

Nelson Leung, Nathan A. Saucier, Steven R. Zeldenrust, Heidi D. Gunderson, Lynn D. Cornell

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from the trials, but several patients have been reported to develop a pre-eclampsia-like syndrome. We report the first case of acute tubular necrosis in a patient with multiple myeloma following treatment with sunitinib.

Original languageEnglish (US)
Pages (from-to)292-294
Number of pages3
JournalNDT Plus
Volume2
Issue number4
DOIs
StatePublished - Aug 1 2009

Keywords

  • acute renal failure
  • drug toxicity
  • sunitinib

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Acute renal failure after treatment with sunitinib in a patient with multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Leung, N., Saucier, N. A., Zeldenrust, S. R., Gunderson, H. D., & Cornell, L. D. (2009). Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. NDT Plus, 2(4), 292-294. https://doi.org/10.1093/ndtplus/sfp037